Abstract
Pancreatic cancer is characterized as a fatal condition and one of the most aggressive and lethal malignancies, with 495,773 new cases anticipated worldwide and 466,003 resultant deaths, establishing a death-to-new-case ratio of 94%. Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of these cases, exhibiting a five-year survival rate ranging from 2% to 9% across various regio…